Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury

Journal of Immunology

Volumn 163, Issue 2, 1999, Pages 985-994

  Heller, Tanja ^a   Hennecke, Meike ^a   Baumann, Ulrich ^a   Gessner, J Engelbert ^a   Meyer Zu Vilsendorf, Andreas ^a   Baensch, Melanie ^a   Boulay, Francois ^b   Kola, Axel ^a   Klos, Andreas ^a   Bautsch, Wilfried ^a   Köhl, Jörg ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; RECEPTOR BLOCKING AGENT;

ARTHUS PHENOMENON; ARTICLE; CALCIUM CELL LEVEL; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CHEMOTAXIS; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNE COMPLEX DISEASE; INFLAMMATION; ISCHEMIA; NEUTROPHIL; PERITONEUM MACROPHAGE; PHAGE DISPLAY; PRIORITY JOURNAL; RECEPTOR BLOCKING; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TISSUE INJURY;

EID: 0033565711     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.163.2.985     Document Type: Article

References (53)

1. Weisman, H. F., T. Bartow, M. K. Leppo, H. C. J. Marsh, G. R. Carson, M. F. Concino, M. P. Boyle, K. H. Roux, M. L. Weisfeldt, and D. T. Fearon. 1990. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146.
2. Makrides, S. C. 1998. Therapeutic inhibition of the complement system. Pharmacol. Rev. 50:59.
3. Liszewski, M. K., and J. P. Atkinson. 1998. Novel complement inhibitors. Exp. Opin. Invest. Drugs 7:323.
4. Thomas, T. C., S. A. Rollins, R. P. Rother, M. A. Giannoni, S. L. Hartman, E. A. Elliott, S. H. Nye, L. A. Matis, S. P. Squinto, and M. J. Evans. 1996. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33:1389.
5. Wang, Y., S. A. Rollins, J. A. Madri, and L. A. Matis. 1995. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA 92:8955.
6. 1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. USA 93:8563.
7. Höpken, U. E., B. Lu, N. P. Gerard, and C. Gerard. 1997. Impaired inflammatory responses in the reverse Arthus reaction through genetic deletion of the C5a receptor. J. Exp. Med. 186:749.
8. Bozic, C. R., B. Lu, U. E. Hopken, C. Gerard, and N. P. Gerard. 1996. Neurogenic amplification of immune complex inflammation. Science 273:1722.
9. Köhl, J., and D. Bitter-Suermann. 1993. Anaphylatoxins. In Complement in Health and Disease, 2nd Ed. K. Whaley, M. Loos, and J. M. Weiler, eds. Kluwer Academic Publishers, Dordrecht, p. 295.
10. Ember, J. A., M. A. Jagels, and T. E. Hugli. 1998. Characterization of complement anaphylatoxins and their biological responses. In The Human Complement System in Health and Disease. J. E. Volanakis and M. M. Frank, eds. Marcel Dekker, New York, p. 241.
11. Gerard, C., and N. P. Gerard. 1994. C5a anaphylatoxin and its seven transmembrane-segment receptor. Annu. Rev. Immunol. 12:775.
12. Stevens, J. H., P. O'Hanley, J. M. Shapiro, F. G. Mihm, P. S. Satoh, J. A. Collins, and T. A. Raffin. 1986. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J. Clin. Invest. 77:1812.
13. Smedegard, G., L. X. Cui, and T. E. Hugli. 1989. Endotoxin-induced shock in the rat: a role for C5a. Am. J. Pathol. 135:489.
14. Höpken, U., M. Mohr, A. Struber, H. Montz, H. Burchardi, O. Götze, and M. Oppermann. 1996. Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. Eur. J. Immunol. 26:1103.
15. Pellas, T. C., W. Boyar, J. van Oostrum, J. Wasvary, L. R. Fryer, G. Pastor, M. Sills, A. Braunwalder, D. R. Yarwood, R. Kramer, E. Kimble, J. Hadala, W. Haston, R. Moreira-Ludewig, S. Uziel-Fusi, P. Peters, K. Bill, and L. P. Wennogle. 1998. Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo. J. Immunol. 160:5616.
16. Ala27. Gene 184:263.
17. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
18. Hennecke, M., A. Otto, M. Baensch, A. Kola, W. Bautsch, A. Klos, and J. Köhl. 1998. A detailed analysis of the C5a anaphylatoxin effector domain: selection of C5a phage libraries on differentiated U937 cells. Eur. J. Biochem. 252:36.
19. Bock, D., U. Martin, S. Gartner, C. Rheinheimer, U. Raffetseder, L. Arseniev, M. D. Barker, P. N. Monk, W. Bautsch, J. Köhl, and A. Klos. 1997. The C terminus of the human C5a receptor (CD88) is required for normal ligand-dependent receptor internalization. Eur. J. Immunol. 27:1522.
20. Köhl, J. 1997. The Anaphylatoxins. In Complement: A Practical Approach. A. W. Dodds and R. B. Sim, eds. Oxford University Press, Oxford, p. 135.
21. Schwenk, U., E. Monta, R. Engel, and J. M. Schroder. 1992. Identification of 5-oxo-15-hydroxy-6,8,11,13-eicosatetraenoic acid as a novel and potent human eosinophil chemotactic eicosanoid. J. Biol. Chem. 267:12482.
22. Gierschik, P., T. Bouillon, and K. H. Jakobs. 1994. Receptor-stimulated hydrolysis of guanosine 5′-triphosphate in membrane preparations. Methods Enzymol. 237:13.
23. Laugwitz, K. L., S. Offermanns, K. Spicher, and G. Schultz. 1993. μ and δ opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma SH-SY5Y cells. Neuron 10:233.
24. Naik, N., E. Giannini, L. Brouchon, and F. Boulay. 1997. Internalization and recycling of the C5a anaphylatoxin receptor: evidence that the agonist-mediated internalization is modulated by phosphorylation of the C-terminal domain. J. Cell Sci. 110:2381.
25. Mery, L., and F. Boulay. 1994. The NH2-terminal region of C5aR but not that of FPR is critical for both protein transport and ligand binding. J. Biol. Chem. 269:3457.
26. Tardif, M., L. Mery, L. Brouchon, and F. Boulay. 1993. Agonist-dependent phosphorylation of N-formylpeptide and activation peptide from the fifth component of C (C5a) chemoattractant receptors in differentiated HL60 cells. J. Immunol. 150:3534.
27. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680.
28. Bitter-Suermann, D., M. P. Dierich, W. Konig, and U. Hadding. 1972. Bypass-activation of the complement system starting with C3. Immunology 23:267.
29. van Dijk, H., P. M. Rademaker, and J. M. Willers. 1980. Estimation of classical pathway of mouse complement activity by use of sensitized rabbit erythrocytes. J. Immunol. Methods 39:257.
30. Bradley, P. P., D. A. Priebat, R. D. Christensen, and G. Rothstein. 1982. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 78:206.
31. Patterson, C. E., R. A. Rhoades, and J. G. N. Garcia. 1992. Evans blue dye as a marker of albumin clearance in cultured endothelial monolayer and isolated lung. J. Appl. Physiol. 72:865.
32. Konteatis, Z. D., S. J. Siciliano, G. Van Riper, C. J. Molineaux, S. Pandya, P. Fischer, H. Rosen, R. A. Mumford, and M. S. Springer. 1994. Development of C5a receptor antagonists: differential loss of functional responses. J. Immunol. 153:4200.
33. Mollison, K. W., W. Mandecki, E. R. Zuiderweg, L. Fayer, T. A. Fey, R. A. Krause, R. G. Conway, L. Miller, R. P. Edalji, M. A. Shallcross, et al. 1989. Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc. Natl. Acad. Sci. USA 86:292.
34. Ember, J. A., S. D. Sanderson, S. M. Taylor, M. Kawahara, and T. E. Hugli. 1992. Biologic activity of synthetic analogues of C5a anaphylatoxin. J. Immunol. 148: 3165.
35. Köhl, J., B. Lubbers, A. Klos, W. Bautsch, and M. Casaretto. 1993. Evaluation of the C-terminal C5a effector site with short synthetic C5a analog peptides. Eur. J. Immunol. 23:646.
36. Kawai, M., D. A. Quincy, B. Lane, K. W. Mollison, J. R. Luly, and G. W. Carter. 1991. Identification and synthesis of a receptor binding site of human anaphylatoxin C5a. J. Med. Chem. 34:2068.
37. Amatruda, T. T., N. P. Gerard, C. Gerard, and M. I. Simon. 1993. Specific interactions of chemoattractant factor receptors with G-proteins. J. Biol. Chem. 268:10139.
38. Jiang, H., Y. Kuang, Y. Wu, A. Smrcka, M. I. Simon, and D. Wu. 1996. Pertussis toxin-sensitive activation of phospholipase C by the C5a and fMet-Leu-Phe receptors. J. Biol. Chem. 271:13430.
39. Ali, H., R. M. Richardson, E. D. Tomhave, J. R. Didsbury, and R. Snyderman. 1993. Differences in phosphorylation of formylpeptide and C5a chemoattractant receptors correlate with differences in desensitization. J. Biol. Chem. 268:24247.
40. Heller, T., J. E. Gessner, R. E. Schmidt, A. Klos, W. Bautsch, and J. Köhl. 1999. Cutting Edge: Fc receptor type I for IgG on macrophages and complement mediate the inflammatory response in immune complex peritonitis. J. Immunol. 162:5657.
41. Sylvestre, D. L., and J. V. Ravetch. 1996. A dominant role for mast cell Fc receptors in the Arthus reaction. Immunity 5:387.
42. Sylvestre, D. L., and J. V. Ravetch. 1994. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 265:1095.
43. Clynes, R., J. S. Maizes, R. Guinamard, M. Ono, T. Takai, and J. V. Ravetch. 1999. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. 189: 179.
44. Clynes, R., C. Dumitru, and J. V. Ravetch. 1998. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279: 1052.
45. Sylvestre, D., R. Clynes, M. Ma, H. Warren, M. C. Carroll, and J. V. Ravetch. 1996. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J. Exp. Med. 184:2385.
46. Amsterdam, E. A., G. L. Stahl, H. L. Pan, S. V. Rendig, M. P. Fletcher, and J. C. Longhurst. 1995. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am. J. Physiol. 268:H448.
47. Eppinger, M. J., G. M. Deeb, S. F. Bolling, and P. A. Ward. 1997. Mediators of ischemia-reperfusion injury of rat lung. Am. J. Pathol. 150:1773.
48. Weiser, M. R., J. P. Williams, F. D. J. Moore, L. Kobzik, M. Ma, H. B. Hechtman, and M. C. Carroll. 1996. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J. Exp. Med. 183:2343.
49. Hill, J., T. F. Lindsay, F. Ortiz, C. G. Yen, H. B. Hechtman, and F. D. J. Moore. 1992. Soluble complement receptor type I ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J. Immunol. 149:1723.
50. Xiao, F., M. J. Eppihimer, B. H. Willis, and D. L. Carden. 1997. Complement-mediated lung injury and neutrophil retention after intestinal ischemia-reperfusion. J. Appl. Physiol. 82:1459.
51. Vakeva, A. P., A. Agah, S. A. Rollins, L. A. Matis, L. Li, and G. L. Stahl. 1998. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 97:2259.
52. Foreman, K. E., A. A. Vaporciyan, B. K. Bonish, M. L. Jones, K. J. Johnson, M. M. Glovsky, S. M. Eddy, and P. A. Ward. 1994. C5a-induced expression of P-selectin in endothelial cells. J. Clin. Invest. 94:1147.
53. Crameri, R., and M. Suter. 1993. Display of biologically active proteins on the surface of filamentous phage: a cDNA cloning system for selection of functional gene products linked to the genetic information responsible for their production. Gene 137:69.